– USA, TX – Perimeter Medical Imaging AI, Inc. (TSX: PINK | OTC: PYNKF | FSE: 4PC), a commercial-stage medical technology company, today announced the appointment of Suzanne Foster as Chair of its Board of Directors, effective immediately.
“Suzanne is a global industry leader with more than 25 years of healthcare experience. Her leadership and industry expertise will be assets to all Perimeter stakeholders in this new capacity. She is one of the longest-serving directors on our Board, and I look forward to continuing to work closely with Suzanne in pursuit of our mission to transform cancer surgery.” said CEO, Jeremy Sobotta.
About Suzanne Foster
Suzanne Foster is the President of Beckman Coulter Life Sciences. She is a global leader with more than 25 years of experience in the healthcare industry. Previously, she held the positions of President of Cardinal Health’s Health-at-Home and VP and GM of Medtronic Advanced Energy. Earlier in her career, she held various legal and compliance roles focused on health systems and healthcare organizations.
“I am excited to take on the role of Chair and support the advancement of Perimeter’s innovative technology with the goal of improving patient outcomes and reducing healthcare costs. When I was going through breast cancer treatment, my surgeon used to say that she could cut out cancer, but real miracles will happen when she can cut out the fear. My hope is that surgeons who use Perimeter’s technology in the OR will reduce the likelihood of a second surgery – but, importantly, also reduce the fears and anxieties of their patients.” said Suzanne Foster.
Ms. Foster holds a B.A. in Communication from the University of New Hampshire, an M.Ed in Psychology from Notre Dame College, a J.D. from Suffolk University Law School, and a Master of Public Health in Law and Health Policy from Harvard T.H. Chan School of Public Health.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada, and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas.
For more information: https://perimetermed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.